{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T18:40:19Z","timestamp":1768588819405,"version":"3.49.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004032","name":"Jilin University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Elderly adults with complicated intra-abdominal infection (cIAI) represent a functionally immunocompromised population due to immunosenescence, multimorbidity, and frailty. Optimizing empirical antibiotic therapy in this group is essential to improve outcomes while minimizing unnecessary broad-spectrum antimicrobial exposure and antimicrobial resistance (AMR) selection pressure. Ertapenem is a once-daily carbapenem with favorable pharmacological properties, yet contemporary real-world comparative data in older adults are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective, real-world comparative-effectiveness study of hospitalized adults aged \u226565 years with cIAI at a tertiary academic medical center from 2019 to 2025. Eligible patients received empirical monotherapy with ertapenem, meropenem, cefoperazone\u2013sulbactam, or moxifloxacin for \u226572 hours. A multinomial propensity score-based inverse probability of treatment weighting (IPTW) approach was used to balance baseline covariates across the four regimens. The primary outcome was clinical cure or improvement. Secondary outcomes included all-cause in-hospital mortality, infection-related mortality, intra-abdominal infection\u2013related mortality, duration of antibiotic treatment, and length of hospitalization. Prespecified subgroup analyses were conducted by age group (65\u201370, 71\u201380, \u226581 years) and infection source (gastrointestinal\n                      <jats:italic>vs<\/jats:italic>\n                      non-gastrointestinal).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 609 patients met eligibility criteria: 129 received ertapenem, 135 meropenem, 125 cefoperazone\u2013sulbactam, and 220 moxifloxacin. IPTW achieved excellent covariate balance, with all standardized mean differences &amp;lt;0.10. In IPTW-adjusted analyses, clinical cure or improvement did not differ significantly between ertapenem and comparator regimens, with adjusted risk differences ranging from 1.80% to 6.44% (all 95% confidence intervals including zero). Mortality outcomes were likewise comparable across groups. Subgroup analyses suggested that ertapenem was associated with higher cure rates and lower mortality in patients aged 65\u201370 years and those with non-gastrointestinal infection sources, although confidence intervals were wide, and these findings should be interpreted as exploratory. Differences in secondary outcomes varied across regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this IPTW-adjusted real-world analysis of elderly adults with cIAI, ertapenem demonstrated clinical effectiveness comparable to meropenem, cefoperazone\u2013sulbactam, and moxifloxacin. Given its once-daily dosing convenience and narrower ecological impact, ertapenem may represent a reasonable and stewardship-aligned empirical option for selected older patients. Prospective and multicenter studies incorporating microbiological and illness severity data are needed to validate these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2025.1759636","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:32:46Z","timestamp":1768545166000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative effectiveness of ertapenem versus other empirical antibiotics in elderly patients with complicated intra-abdominal infection: a real-world inverse probability of treatment weighting study"],"prefix":"10.3389","volume":"15","author":[{"given":"Yao","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Pharmacy, China\u2013Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiming","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, China\u2013Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haizhen","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, China\u2013Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueyao","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, China\u2013Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, China\u2013Japan Union Hospital of Jilin University","place":["Changchun, China"]},{"name":"School of Pharmaceutical Sciences, Jilin University","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-9-193","article-title":"Ertapenem versus piperacillin\/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials","volume":"9","author":"An","year":"2009","journal-title":"BMC Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106591","article-title":"Epidemiology and age-related mortality in critically ill patients with intra-abdominal infection or sepsis: an international cohort study","volume":"60","author":"Arvaniti","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.chest.2023.08.008","article-title":"Comparative effectiveness of first-line and alternative antibiotic regimens in hospitalized patients with nonsevere community-acquired pneumonia: A multicenter retrospective cohort study","volume":"165","author":"Bai","year":"2024","journal-title":"Chest"},{"key":"B6","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in elderly people","volume":"381","author":"Clegg","year":"2013","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12979-019-0164-9","article-title":"Immunosenescence and human vaccine immune responses","volume":"16","author":"Crooke","year":"2019","journal-title":"Immun. Ageing"},{"key":"B8","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/j.1365-2036.2008.03642.x","article-title":"Meta-analysis: ertapenem for complicated intra-abdominal infections","volume":"27","author":"Falagas","year":"2008","journal-title":"Aliment Pharmacol. Ther."},{"key":"B9","volume-title":"Causal Inference: What If.","author":"Hernan","year":"2020"},{"key":"B10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.amsu.2014.06.005","article-title":"Antibiotic management of complicated intra-abdominal infections in adults: The Asian perspective","volume":"3","author":"Kurup","year":"2014","journal-title":"Ann. Med. Surg. (Lond)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1616184","article-title":"Real-world efficacy and safety of cefepime for pediatric community-acquired pneumonia: a propensity score-matched study","volume":"15","author":"Liu","year":"2025","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/sur.2016.261","article-title":"The surgical infection society revised guidelines on the management of intra-abdominal infection","volume":"18","author":"Mazuski","year":"2017","journal-title":"Surg. Infect. (Larchmt)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"6277","DOI":"10.2147\/IDR.S429706","article-title":"Risk factors for cefoperazone\/sulbactam-induced coagulation disorder","volume":"16","author":"Miao","year":"2023","journal-title":"Infect. Drug Resist."},{"key":"B15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1089\/sur.2006.030","article-title":"Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin\/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults","volume":"8","author":"Namias","year":"2007","journal-title":"Surg. Infect. (Larchmt)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"ii23","DOI":"10.1093\/jac\/dkh205","article-title":"Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians","author":"Nix","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1186\/1749-7922-9-37","article-title":"Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study","volume":"9","author":"Sartelli","year":"2014","journal-title":"World J. Emerg. Surg."},{"key":"B20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13017-017-0141-6","article-title":"The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections","volume":"12","author":"Sartelli","year":"2017","journal-title":"World J. Emerg. Surg."},{"key":"B21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13017-017-0148-z","article-title":"Erratum to: The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections","volume":"12","author":"Sartelli","year":"2017","journal-title":"World J. Emerg. Surg."},{"key":"B22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13017-021-00387-8","article-title":"WSES\/GAIS\/SIS-E\/WSIS\/AAST global clinical pathways for patients with intra-abdominal infections","volume":"16","author":"Sartelli","year":"2021","journal-title":"World J. Emerg. Surg."},{"key":"B23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13017-024-00551-w","article-title":"Management of intra-abdominal infections: recommendations by the Italian council for the optimization of antimicrobial use","volume":"19","author":"Sartelli","year":"2024","journal-title":"World J. Emerg. Surg."},{"key":"B24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13017-016-0089-y","article-title":"Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA)","volume":"11","author":"Sartelli","year":"2016","journal-title":"World J. Emerg. Surg."},{"key":"B25","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1186\/s12879-019-4604-0","article-title":"Intra-abdominal infections: the role of different classifications on the selection of the best antibiotic treatment","volume":"19","author":"Silva-Nunes","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1086\/649554","article-title":"Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America","volume":"50","author":"Solomkin","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/01.SLA.0000048551.32606.73","article-title":"Ertapenem versus piperacillin\/tazobactam in the treatment of\u00a0complicated intraabdominal infections: results of a double-blind, randomized\u00a0comparative phase III trial","volume":"237","author":"Solomkin","year":"2003","journal-title":"Ann. Surg."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1759636\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:32:47Z","timestamp":1768545167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1759636\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":27,"alternative-id":["10.3389\/fcimb.2025.1759636"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1759636","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"article-number":"1759636"}}